A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science
Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.
Authors
- Nosakhare Paul Ilerhunmwuwa (ORCID: https://orcid.org/0000-0002-4950-5611)
- Jeffrey Mathew Boby (ORCID: https://orcid.org/0009-0005-0975-9157)
- Paola Zinser Peniche
- Doga Kahramangil Baytar
- Jame Mathew Benny
- Ibrahim Halil Sahin
Institutions
- University of Pittsburgh (US)
- University of Michigan (US)
- Government Medical College (IN)
- Government Medical College (IN)
Publication Details
- Journal
- Cancer Investigation
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1080/07357907.2026.2636581
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00